Combination therapies are the future of cancer care, but pharmaceutical regulation is lagging behind


Access to new combination therapies against cancer is lacking throughout Europe and highly heterogeneous, even within countries, according to a new study by the Netherlands Cancer Institute and the European Fair Pricing Network that mapped access to 23 combination therapies for melanoma and lung cancer. The main reason is that the entire drug development chain is focused on classical monotherapies.

Publication: ‘Targeted combination therapies in oncology: Challenging regulatory frameworks designed for monotherapies in Europe’, Drug discovery today, August 2023 (open access).

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.